Board Approves Key Appointments and Strategic Acquisitions, Reports Financials for Q2 FY26

Board Approves Key Appointments and Strategic Acquisitions, Reports Financials for Q2 FY26​

Sai Parenterals Limited announced significant changes in its management structure and strategic asset allocation following a Board Meeting held on August 11, 2026. The meeting addressed re-appointments of key directors, the appointment of new executive leadership, operational resignations, and approved material variations concerning the utilization of IPO proceeds for corporate expansion.

The board decisions included the re-appointment of Mr. Anil Kumar Karusala as Managing Director, Mrs. Vijitha Gorrepati as Whole-time Director, and the appointment of Mr. Kunal Kakumanu as an Additional and Executive Director. Additionally, Ms. Shivali Aggarwal tendered her resignation as Company Secretary and Compliance Officer, while Mrs. Aruna Karusala resigned from her position as Non-Executive Director.

The meeting also reviewed several strategic business variations, including the acquisition of equity stakes in two pharmaceutical entities. The company decided to allocate Rs 838.34 million, originally earmarked for upgrading manufacturing facilities (Unit I and Unit II) to meet EU-GMP standards, towards acquiring a 60% equity stake in Saicriti Pharma Private Limited. This new venture involves the development of a critical care sterile injectable manufacturing facility at Gummadidala, Hyderabad.

Similarly, Rs 180.23 million, originally set aside for establishing an internal research and development (R&D) centre, will now be utilized to acquire a 60% equity stake in Prathyak Laboratories Private Limited. This acquisition provides the company with an established pharmaceutical R&D platform possessing a portfolio of 124 products.

Financial Performance Overview​

The company reported its unaudited financial results for the quarter ended June 30, 2026.

Standalone Financial Highlights (Qended June 30, 2026)

Consolidated Financial Highlights (Qended June 30, 2026)

Subsidiary Performance​

The company has five subsidiaries, including two step-down entities that operate internationally. The financial performance of the group's key subsidiaries and step-down companies is summarized below:


The company also confirmed the incorporation of a new Wholly Owned Subsidiary in the United States of America, which operates in the Pharma Sector and holds a 100% shareholding.

SAIPARENT Stock Price Movement​

Shares of Sai Parenterals Limited today slipped by 1.28% to settle at ₹573.50, closing down ₹7.50 from the previous close. The equity traded in a range spanning from ₹570 to ₹593.1, with 119,738 shares changing hands during the session.